Monday, September 19, 2016
Ignyta, EORTC In Collaboration Deal
San Diego-based biotechnology developer Ignyta, and the European Organisation for Research and Treatment of Cancer (EORTC) said this morning that the two are in a new collaboration deal, will Ignyta will serve as a diagnostic laboratory performing fusion testing for EORTC's SPECTA (Screening Patients for Efficient Clinical Trial Access) initiative. Financial impact of the deal were not announced. The collaboration is aimed at improving the effectiveness of treating cancer patients. EORTC focuses on patients with colorectal, brain, lung, melanoma and rare cancers.